Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Orphan drugs].

J Kolár1, M Chalabala, H Srámková

  • 1Ustav aplikované farmacie Farmaceutické fakulty Veterinární a farmaceutické univerzity, Brno. kolar@vfu.cz

Ceska a Slovenska Farmacie : Casopis Ceske Farmaceuticke Spolecnosti a Slovenske Farmaceuticke Spolecnosti
|April 6, 2001
PubMed
Summary

This paper examines government approaches to orphan drugs, focusing on legislation and financial incentives in the USA, Japan, and Europe to ensure rare disease patients access vital treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hetastarch induced volume changes of starving adenoma and suggested mechanism of action.

Scientific reports·2022
Same author

Patterns in anticoagulant utilization in the Czech Republic during 2007-2017.

Journal of thrombosis and thrombolysis·2019
Same author

[20TH HUMAN-IN-SPACE SYMPOSIUM OF THE INTERNATIONAL ACADEMY OF ASTRONAUTICS].

Aviakosmicheskaia i ekologicheskaia meditsina = Aerospace and environmental medicine·2016
Same author

Structure of amorphous Ag/Ge/S alloys: experimentally constrained density functional study.

Journal of physics. Condensed matter : an Institute of Physics journal·2015
Same author

Silver environment and covalent network rearrangement in GeS3-Ag glasses.

Journal of physics. Condensed matter : an Institute of Physics journal·2013
Same author

Compressive syndrome of internal jugular veins in multiple sclerosis: does it matter?

Phlebology·2012

Area of Science:

  • Pharmacoeconomics
  • Health Policy
  • Regulatory Affairs

Context:

  • Orphan drugs address rare diseases affecting small patient populations.
  • Global regulatory frameworks and financial incentives significantly impact orphan drug development and accessibility.
  • Disparities exist in how authorities define and legislate for orphan drugs across major markets.

Purpose:

  • To analyze the legislative and financial strategies employed by state authorities in the USA, Japan, and Europe concerning orphan drugs.
  • To evaluate the effectiveness of these strategies in ensuring patient access to treatments for rare diseases.

Summary:

  • The study reviews the definition and legislative frameworks for orphan drugs in the USA, Japan, and the European Union.
  • It assesses financial provisions, production considerations, and exclusive sale rights as mechanisms to guarantee drug availability for rare disease patients.
  • Comparative analysis highlights differing national approaches to fostering orphan drug development and market entry.

Impact:

  • Provides insights for policymakers seeking to optimize orphan drug legislation and incentives.
  • Informs pharmaceutical companies on navigating regulatory landscapes for rare disease treatments.
  • Contributes to the discourse on equitable access to medicines for patients with rare conditions.

Related Experiment Videos